Drug details
Rydapt (midostaurin capsules)
type of Antineoplastic Tyrosine Kinase Inhibitors
Rydapt (midostaurin) capsules are a kinase inhibitor indicated for the treatment of adult patients with Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Rydapt is not indicated as a single-agent induction therapy for the treatment of patients with AML. Rydapt is also indicated for treatment of aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
This drug may have the following side effects:
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- fever,
- easy bruising,
- unusual bleeding,
- pale skin,
- shortness of breath,
- chills,
- tiredness,
- chest pain,
- dry mouth,
- wheezing,
- sore throat,
- increased thirst,
- increased urination,
- fruity breath odor,
- lightheadedness
- skin sores,
- warmth,
- redness,
- tingly feeling,
- dry cough,
- cold hands and feet, and
- pain or sores in or around your mouth,
- redness inside your mouth,
- bruising, swelling, warmth, redness, oozing, or bleeding around the needle,
The following drugs are related to Rydapt, either as a replacement or used together:
- Sprycel (dasatinib)
- Daurismo (glasdegib tablets)
- Inqovi (decitabine and cedazuridine tablets)
- Xospata (gilteritinib tablets)
- Gleevec (imatinib mesylate)